Alloy Review: The Widest Approved GLP-1 Range We've Reviewed — With $99 a Month Added to Every Price

What Is Alloy?

Alloy is a telehealth company built around menopause and midlife women's health. Its main business is hormone therapy — estradiol pills, patches, gels and Evamist — with additional lines covering skincare, sexual health, hair, and a gut synbiotic. Weight care sits alongside those under the heading "Weight care made for midlife," and it is a substantial offering rather than an afterthought.

The range is the standout. On the FDA-approved side Alloy lists Zepbound and the Zepbound KwikPen from $299 a month, the Wegovy pen from $199 (displayed marked down from $499), the Wegovy pill from $149, and the Foundayo pill from $149. On the compounded side it lists semaglutide from $70, tirzepatide from $100 and liraglutide from $115. Being able to start on a compounded product and move to an approved one — or the reverse, if cost becomes the constraint — without changing provider is a practical advantage that most of the companies in this series cannot offer.

Carrying both oral GLP-1s is genuinely unusual. Wegovy tablets were approved by the FDA in December 2025 under NDA 218316, with the label stating that in patients without type 2 diabetes, average semaglutide blood concentrations on 25mg once daily and on the 2.4mg weekly injection were similar. Foundayo is orforglipron, approved on 1 April 2026 under NDA 220934 — we confirmed both in the FDA's own Drugs@FDA records rather than taking the company's word for it. For anyone who will not inject, these are the two products that actually have FDA review behind them, and Alloy sells both.

The clinical framing is the other real differentiator, and it is more than marketing. Alloy's line is "Menopause experts, not generalists." Weight gain in the perimenopausal transition is common, frequently mishandled, and interacts with hormone therapy decisions — so a service that prescribes GLP-1s and HRT from the same clinical team, with the stated ability to consider them together, is addressing something real. The intake is quick: a 5 to 10 minute questionnaire, a treatment plan in under 12 hours, and free delivery.

Medications Offered & Pricing

Prices checked on myalloy.com on 8 August 2026, and every one of them is a "starting at" figure that excludes the mandatory $99 monthly Weight Care fee. The company does state the fee plainly elsewhere — "$99/month plus the cost of medication" — so this is disclosure placed awkwardly rather than concealment, but the arithmetic matters. Compounded semaglutide at $70 is $169 a month all-in. Compounded tirzepatide at $100 is $199. The Wegovy pill and Foundayo at $149 are $248. Zepbound at $299 is $398. A $50 discount on the first month applies to new customers with the code STARTGLP1. Because these are all "starting at" prices, higher doses will cost more than shown, and the site does not publish a dose-by-dose table.

Brand-Name or Compounded?

Alloy is in the comparatively rare position of not needing the compounding argument to work, because it sells approved products too. That materially changes the risk calculus for a patient and is the strongest structural point in its favour.

The context still applies to its compounded lines. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025. Enforcement discretion for compounding tirzepatide injection products ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities; for semaglutide the equivalent deadlines were 22 April and 22 May 2025. In a notice published on 1 May 2026, with comments closing 29 June 2026, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely, having found no clinical need for outsourcing facilities to compound them from bulk substances. Note that liraglutide is named in that proposal and Alloy sells compounded liraglutide.

Compounding a commercially available drug is lawful under section 503A where the preparation is not essentially a copy of the approved product, which generally turns on a documented clinical need for the individual patient. We cannot assess how Alloy's prescribers apply that, and we are not suggesting anything improper. What we can say is that a patient here is not dependent on the outcome: if compounded supply becomes constrained, Alloy has five FDA-approved products on the same menu and a prescriber relationship already in place. Patients at compounded-only providers do not have that.

The honest framing for a reader choosing between them: compounded semaglutide at $169 a month all-in is genuinely cheaper than Foundayo or the Wegovy pill at $248, and cost is a legitimate basis for that choice. What it is not is an equivalent product. The approved medicines have been reviewed by the FDA for safety, effectiveness and manufacturing quality; compounded preparations have not, and are not generic versions of the branded drugs. If the price difference is not decisive for you, the approved option is the better-evidenced one.

Alloy does not name its compounding pharmacy partners on the pages we reviewed, which is the norm in this sector and still a shortcoming — you cannot check whether a facility is a 503A pharmacy or a 503B outsourcing facility, or look up its inspection history.

The Consultation Process

Eligibility

• •A prescription is required, issued after clinician review of your intake.
• •The service is oriented toward women in perimenopause, menopause and midlife generally, though weight care is not stated to be restricted by age.
• •Alloy is not available in Alabama, Arkansas, California, Nevada, Louisiana, Mississippi or the District of Columbia — check before starting, particularly as California is excluded.
• •Specific published BMI or comorbidity thresholds for the weight programme were not disclosed on the pages we reviewed.
• •Whether baseline lab work is required for weight care was not stated on the pages we could access.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

Free delivery to your door is stated across the weight care pages, with a treatment plan returned in under 12 hours. Beyond that the published detail is thin: we found no statement of carriers, delivery windows, or — most importantly for injectable GLP-1s — cold-chain handling and temperature control in transit. Providers we have rated well on this point publish the temperature range and packing method. Ask Alloy before your first order.

• •The support model is the product. Unlimited messaging with an Alloy physician is included in the $99 monthly fee, alongside ongoing care, dose adjustments and a personalised plan covering nutrition. That is a more substantive offer than the asynchronous, prescription-only model used by several cheaper competitors.
• •Alloy publishes a medical team page, a founders' story, patient reviews and an editorial section called The Flash, plus a referral route for clinicians. The company presents itself as a clinical service rather than a storefront, and the material supports that.
• •We could not retrieve Alloy's cancellation or refund terms. The FAQ page is rendered client-side and did not yield text to automated retrieval, and the site's footer links to a privacy policy and terms of use but not to a refund or returns policy we could locate. That is a real gap in this review and we would rather say so than infer terms we have not read.
• •We found no Better Business Bureau profile or substantial independent complaint corpus for Alloy, so we cannot characterise how it handles disputes in practice.

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Alloy May Be Best For

• •Women in perimenopause or menopause whose weight change is bound up with hormonal transition and who want both addressed by the same clinicians
• •Anyone who wants an FDA-approved oral GLP-1 — this is one of the few places carrying both Wegovy tablets and Foundayo
• •Patients who want the option to move between compounded and approved medication without switching provider
• •People who will actually use unlimited physician messaging, which is what the $99 fee buys
• •Buyers who want a branded injectable and a clinician relationship rather than a prescription-only transaction

Limitations

• •The $99 fee is the main pricing criticism and it compounds across the catalogue. Every headline is $99 short of reality, so the cheapest entry point is $169 a month rather than $70. Alloy does state the fee elsewhere, so this is placement rather than concealment — but a reader comparing providers on advertised prices will systematically underestimate this one.
• •Seven excluded jurisdictions is a lot, and California being among them removes the largest state in the country. Check availability before investing time in the intake.
• •The absence of published cancellation and refund terms is the gap that concerns us most, precisely because the fee recurs monthly. Every other criticism here is about a number being in the wrong place; this is about a term we could not read at all. Get it in writing before you start.
• •Compounded liraglutide sits in a narrower position than the company's other compounded lines: it is one of the three drugs the FDA proposed removing from the 503B bulks list in May 2026, and it requires daily injection rather than weekly, which is a tolerability consideration as well as a supply one.
• •No cold-chain disclosure for injectables. GLP-1s degrade if they warm up, and the better providers in this series publish their temperature range and packing method. Alloy does not, and free delivery says nothing about refrigerated delivery.
• •"Starting at" pricing without a dose table means the number you plan around may not be the number you pay at maintenance dosing, which is where most patients spend most of their time.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Alloy has assembled the most complete GLP-1 menu we have reviewed, and it did so in the way that most benefits patients: by carrying the approved products rather than only the cheap ones.

Both FDA-approved oral GLP-1s are here — Wegovy tablets from December 2025 and Foundayo from April 2026 — alongside Zepbound, the KwikPen, the Wegovy pen, and compounded semaglutide, tirzepatide and liraglutide. That range does something structural for a patient: it means the compounding question is not existential. If compounded supply tightens further, and the FDA's May 2026 proposal suggests it may, a patient here moves to an approved product with the same prescriber. A patient at a compounded-only service starts over somewhere else. Layer on menopause-specialist prescribing and unlimited physician messaging, and this is a serious clinical service rather than a storefront.

The pricing presentation is the flaw, and it is the same one we have criticised elsewhere this week. Every medication price on the site is a "starting at" figure with a mandatory $99 monthly fee omitted. The entry point is not $70, it is $169. Zepbound is not $299, it is $398. Alloy does disclose the fee, and what it buys — unlimited access to a specialist physician — is a real service that some patients will use heavily and consider good value. But the number a shopper compares against rivals is wrong on every line, and fixing that is a presentational choice, not a commercial sacrifice.

The gap that concerns us more is that we could not read the cancellation or refund terms at all. For a service with a recurring monthly charge, that is the term a prospective patient most needs, and it was not available on any page we could access. We have not inferred it and we would advise nobody else to. Get it in writing before the first charge. The same applies to cold-chain handling: free delivery of an injectable that must stay between 36 and 46°F tells you nothing about whether it will.

Rated 3.8 out of 5, the highest in this batch. If you are a midlife woman who wants weight care from clinicians who understand what perimenopause does to metabolism, or you specifically want an FDA-approved GLP-1 pill, this is a strong option and the range genuinely justifies a membership model. Budget the $99, check that your state is not one of the seven excluded, ask about cancellation and refrigerated shipping before you pay, and if cost is the deciding factor be clear with yourself that the $70 compounded option is a $169 option that has not been through FDA review.